Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

PHASE2RecruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Osteoarthritis
Interventions
BIOLOGICAL

[StroMed + platelet rich plasma (PRP)]

Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 \[StroMed + platelet rich plasma (PRP)\], Day 7, 14 and 30 \[PRP\]

Trial Locations (1)

16127

RECRUITING

VivaTech International, Inc., Grove City

All Listed Sponsors
lead

VivaTech International, Inc.

INDUSTRY

NCT02844764 - Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip | Biotech Hunter | Biotech Hunter